Congressional Pressure Mounts On PBMs, But Skepticism Remains About Near-Term Action

Attention on PBMs with minimal risk of policy change may represent the best of both worlds for pharma, which benefits from another part of the industry taking the heat on drug prices but could stand to lose out financially depending on the PBM reform approaches taken.

person touching opaque surface — House Republicans tee up deep dive into opaque PBM practices. • Source: Shutterstock

The Republican-led House Oversight committee launched an investigation into pharmacy benefits managers on 1 March, adding to the wave of probes the industry has faced in recent years.

But in perhaps classic Washington style, where it is far easier to probe then legislate, there remains a lack of...